See what’s new.
New Frontiers in Space
Satellite antenna can take images faster and more often than existing technology, allowing us to track the Earth as it evolves. Extellis is an inventor booth at Invented at Duke 2024.
Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B
Tune Therapeutics is a Duke University start-up and Duke Capital Partners portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).
Injecting Hope
Researchers say injectable gel-like substance has healing powers for bone injuries. OsteoCure is an inventor booth at Invented at Duke 2024.
Early-stage startups meet potential investors, partners at Triangle Venture Day
A total of 20 Triangle startups – including 4 with Duke roots – pitched their ideas to an audience that included more than 50 investor and strategic partnership groups at the Raleigh Convention Center.
The Hard-Earned Lessons of Academic Entrepreneurs
Pratt I/O Magazine – Faculty entrepreneurs from Duke Engineering share their experiences of what it takes to spin a startup out of a university.
EydisBio Receives FDA Orphan Drug Designation for TAK1 Inhibitor for the Treatment of Systemic Sclerosis
EydisBio is a start-up founded by Professor Timothy Haystead (P&CB, SOM) focusing on the treatment of autoimmune and inflammatory diseases.
Duke Inventions Bring $82.6M in Revenue and Launch 6 New Start-Ups
$82.6M in revenue. 94 patents issued. 302 new invention disclosures. In a down year for new disclosures, OTC focuses on investing in the future.
Sparta Biomedical Reports Treatment of First Patients with Breakthrough Device, Ormi
Sparta Biomedical, a Duke start-up and Duke Capital Partners portfolio company, was founded around technology developed by lead inventor Professor Benjamin Wiley (Chemistry, Trinity), along with Professor Ken Gall (MEMS, Pratt), Professor Matt Becker (Chemistry, Trinity), and colleagues.
Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke
Basking Biosciences, a start-up out of the lab of Professor Bruce Sullenger (Surgery, SOM), is developing a next-generation treatment for acute ischemic stroke.